FDA approves new drug doubling survival rate for pancreatic cancer patients
Aug 27, 2026
Washington [US], August 27: The Food and Drug Administration (FDA) has granted approval for a novel oral therapy developed by Revolution Medicines, following late-stage clinical trials showing it can double survival times for individuals with advanced pancreatic cancer.